BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib+rituximab or bendamustine+rituximab in BTKi-pretreated CLL/SLL Meeting Abstract


Authors: Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L. E.; Burke, J. M.; Chen, C.; Grzasko, N.; Follows, G.; Mátrai, Z.; Sanna, A.; Yi, S.; Hua, V. M.; Feng, R.; Holodja, J.; Jurczak, W.; Ritgen, M.; Qiu, L.; Bosch, F.; Coombs, C. C.; Bao, K.; Patel, V.; Liu, B.; Compt, L.; Guntur, A.; Wang, D. Y.; Hill, M.; Leow, C. C.; Ghia, P.; Barr, P. M.; Chan, T. W.
Abstract Title: BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib+rituximab or bendamustine+rituximab in BTKi-pretreated CLL/SLL
Meeting Title: 65th Annual Scientific Meeting of the British Society for Haematology (BSH)
Journal Title: British Journal of Haematology
Volume: 206
Issue: Suppl. 1
Meeting Dates: 2025 Apr 27-29
Meeting Location: Glasgow, Scotland
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2025-04-01
Language: English
ACCESSION: WOS:001517858300220
PROVIDER: wos
DOI: 10.1111/bjh.20117
Notes: Meeting Abstract: PO84 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lindsey Elizabeth Roeker
    146 Roeker